If retatrutide shows cardiovascular benefit similar to or better than semaglutide, it would significantly strengthen the case for approval and potentially expand the labeled indications
USP 797 sterile compliance, ISO-classified cleanrooms, PCAB, ACHC, and NABP accreditation, active ingredients from FDA-inspected suppliers, and independent potency and sterility testing on finished preparations
Retatrutide is currently the most effective drug ever tested for weight loss, based on the latest clinical trial data
Semaglutide 2.4 mg achieved a mean change in body weight from baseline to week 104 of -15.2% in the phase 3b STEP 5 trial, and 77.1% of participants achieved weight loss 5% from baseline at week 104
225 mg: for a 10 mg dose 6 months, or for those on even higher doses